Tracking a lung cancer Drug's Real-World performance in china
NCT ID NCT05721950
Summary
This study is observing how well the drug brigatinib works for Chinese adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in real-world medical settings. Researchers are not giving any new treatment; they are collecting data from about 200 patients who are already taking brigatinib as their first cancer therapy. The main goal is to see how long patients stay on the treatment and how it affects their cancer progression and survival over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Shanghai pulmonary hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.